Safety in Ovarian Cancer for Average-Risk Women - Analysis

Part of paid clinical trials in Waltham, Massachusetts.

Sponsor: Mercy BioAnalytics, Inc.
Study ID: NCT07872644
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Ovarian Cancer

Eligibility Criteria

Sex: FEMALE
Age: 50 Years - N/A
Healthy Volunteers: Accepted

Interventions

Blood-Based Ovarian Cancer Screening Test — DIAGNOSTIC_TEST
A blood sample will be collected and analyzed using an investigational blood-based ovarian cancer screening test. Participants with positive screening results will be advised to undergo follow-up transvaginal ultrasound (TVUS) and may elect repeat blood-based testing. Additional clinical evaluation is determined by their healthcare provider.

Study Details

This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.

Key Dates

First listed: Oct 13, 2026
Start date: Nov 30, 2026
Status verified: Oct 2026
Primary completion: May 31, 2028
Completion: May 31, 2028

Study Design

Enrollment: 1,750 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Arms

Experimental: Average-Risk
Postmenopausal women aged 50 years or older with no known current ovarian cancer, other active malignancy, or established ovarian cancer risk factors. The study will aim to enroll a diverse population generally representative of the US population with respect to race and ethnicity.